Updated draft guidance released by the US Food and Drug Administration (FDA) in March 2019 on naming conventions for biologics and biosimilars has provoked a strong pushback from the local and global biosimilars industry.
FDA Commissioner Scott Gottlieb summarized the key points of the guidance – which reiterates the agency’s intention to use four-letter suffixes to non-proprietary names for all biosimilars, just days after...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?